There are currently 53 clinical trials in Waco, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including GSK Investigational Site, Texas Oncology, Allergy Asthma Research Institute and Teva Investigational Site 14948. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Acute Effects of Whole Body Vibration for Individuals With Parkinson Disease
Recruiting
This is an exploratory study to assess the impact of whole body vibration on backward walking speed in people with Parkinson disease.
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
04/03/2024
Locations: Baylor University, Waco, Texas
Conditions: Parkinson Disease
Activities-based Locomotor Training Program Versus Traditional Physical Therapy in Children With Cerebral Palsy
Recruiting
The purpose of this study is to investigate the impact of an intensive activities-based locomotor training program as compared to traditional physical therapy on activity, participation, and central and peripheral neurophysiological adaptation in children with cerebral palsy.
Gender:
All
Ages:
Between 2 years and 6 years
Trial Updated:
04/01/2024
Locations: Baylor University, Waco, Texas
Conditions: Cerebral Palsy
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
Recruiting
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Impact Research Institute, Waco, Texas +1 locations
Conditions: NASH, Cirrhosis, Liver
Phase 2b Study of GSK4532990 in Adults With NASH
Recruiting
The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4). The study duration will be up to 76 weeks including the screening period. The treatment duration will be up to 52 weeks.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/13/2024
Locations: GSK Investigational Site, Waco, Texas
Conditions: Nonalcoholic Fatty Liver Disease
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
03/11/2024
Locations: Research Site, Waco, Texas
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
National Sponsorship Program for Transitioning Service Members
Recruiting
Background: The United States is undergoing a suicide epidemic for its youngest Veterans (18-to-34-years-old) as their suicide rate has almost doubled since 2001. Veterans are at the highest risk during their first-year post-discharge, thus creating a "deadly gap" for them. In response, the nation has developed strategies that emphasize a preventive, universal and public health approach and embrace the value of community interventions. The three-step theory of suicide suggests that community in... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/29/2024
Locations: Central Texas Veterans Health Care System Waco VA Medical Center, Waco, TX, Waco, Texas
Conditions: Reintegration Difficulties, Health, Suicidal Ideation and Behaviors, Connectedness
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/14/2024
Locations: Allergy Asthma Research Institute, Waco, Texas
Conditions: Refractory Chronic Cough
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Impact Research Institute, Waco, Texas +1 locations
Conditions: NASH - Nonalcoholic Steatohepatitis
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis
Recruiting
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
12/30/2023
Locations: Zydus US078, Waco, Texas
Conditions: Nonalcoholic Steatohepatitis, Fibrosis
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/20/2023
Locations: Texas Oncology - Waco, Waco, Texas
Conditions: Breast Cancer
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Recruiting
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Impact Research Institute, Waco, Texas
Conditions: Non-Alcoholic Fatty Liver Disease
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE.
Gender:
All
Ages:
Between 12 years and 70 years
Trial Updated:
11/16/2023
Locations: Waco Site, Waco, Texas
Conditions: Systemic Lupus Erythematosus